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Abstract
Primary synovial sarcoma of the heart is very rare, accounting for 5% of cardiac malignan-
cies. Of the few cases reported in the literature to date, nearly all have had a very poor outcome.
We present a further case. This uncommon malignancy has no specific symptoms during its
development, which results in delayed diagnosis. Echocardiography, chest computed tomogra-
phy, and magnetic resonance imaging can provide effective information about this tumor.
With the identification of the characteristic and diagnostic chromosomal abnormality t(X; 18),
this malignancy will become increasingly recognized. Synovial sarcoma of the heart requires
surgical intervention to improve the prognosis. Adjuvant and/or genetic therapy pre- or post-
operation can help prolong life. Chemotherapy is usually recommended as it may benefit the
patients. The key to treatment in the future is to find new therapeutic agents. Further elucida-
tion of the effects of this chromosomal abnormality may lead to better-directed therapies in
future. (Cardiol J 2011; 18, 2: 128–133)
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Introduction
The incidence of primary malignant tumor of
the heart is extremely low: about 0.02% in a series
of autopsies [1, 2]. The incidence among the gene-
ral population varies between 0.001% and 0.03% [3].
Nearly all are sarcomas: the commonest are an-
giosarcomas (31%), followed by rhabdosarcomas
(21%), malignant mesotheliomas (15%) and fibro-
sarcomas (11%) [4, 5], with synovial sarcomas only
accounting for 5% of malignant tumors of the heart
[6–8]. Primary synovial sarcoma of the heart is
mentioned in the literature mainly as case reports.
It is easy for diagnosis to be delayed due to the non-
specific clinical symptoms. No effective treatment
measures exist, and the prognosis is very poor, with
most patients succumbing within 12 months of dia-
gnosis. We describe a new case and review the pre-
vious reports.
Case report
A 39 year-old male patient was referred to our
hospital after four months of continuous coughing,
expectoration and hemoptysis, initially presumed
to be a lung infection, but unresponsive to anti-infec-
tive drugs. A chest computed tomographic (CT) scan
revealed an enlarged heart with a right ventricular
mass. The electrocardiogram showed normal sinus
rhythm with complete right bundle branch block and
abnormal T-wave. Transthoracic echocardiography
detected echo zones in the right ventricular cham-
ber, in the free wall and pericardial cavity outside
the right ventricle (Fig. 1A). A subsequent 64-slice
CT scan accurately demonstrated a 9.5 cm × 6.2 cm
right ventricular mass with intraventricular and
extraventricular extensions. The right ventricular
wall and the ventricular septum were invaded.
Slight pericardial and bilateral pleural effusions
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were found as well (Figs. 1B, C). Laboratory find-
ings showed: erythrocyte sedimentation rate (ESR)
was 54 mm/h (0–15 mm/h); C-reactive protein was
117.2 mg/L (< 8 mg/L); neuron specific enolase
(NSE) was 47.74 µg/L (0–16.3 µg/L); hemoglobin
was 109 g/L; leukocyte was 17.7 × 109/L; neutrophilic
granulocyte proportion was 0.81; while liver and
kidney functions, as well as all other tumor mark-
ers, were within the normal range. No abnormal
lesions were observed in head or abdominal scan-
ning. A tumor biopsy under the guidance of digital
subtraction angiography (DSA) revealed some eosin
staining exudates without a definite pathological
outcome. The decision was made to perform a tu-
mor resection, both for diagnosis and restoration of
hemodynamic stability. Following median sterno-
tomy, the pericardium was dissected to reveal slight
pericardial effusion and a 5 cm × × 4 cm × 4 cm
reddish extraventricular tumor covering the ante-
rior wall of the right ventricle with old thrombi on
the surface (Fig. 1D). The coronary artery was un-
affected. After instituting cardiopulmonary bypass
via the vena cava and ascending aorta, systemic
cooling to 32 degrees centigrade, complete aorta
and pulmonary artery block, and cardioplegia to ar-
rest the heart, the right atrium was incised.
Through the enlarged tricuspid annulus, it was no-
ticed that the intraventricular portion of the tumor
almost completely filled the right ventricle; part of
the right ventricular septum was invaded. The tri-
cuspid valve and right ventricular outflow tract were
seriously obstructed by the tumor. The large tumor
size and the important surrounding heart structures
prevented a complete surgical resection of the tu-
mor. A partial removal of the tumor was finally car-
ried out. Most of the intraventricular tumor was re-
sected to relieve the right ventricular inflow and
outflow tract obstruction. The extraventricular part
was completely removed, and part of the right ven-
tricular free wall was cut off, leaving a 4 cm × 3 cm ×
× 3 cm defect. The right ventricular reconstruction
was performed with a vascular graft patch (Inter-
Vascular, a Datascope company, Montvale, NJ,
USA). Tricuspid annuloplasty was performed. Even-
tually a 6 cm × 5 cm × 4 cm part of the tumor was
resected (Fig. 1E) and a reconstructive right ven-
tricle and unblocked right ventricular inflow and
outflow tract were achieved. The patient received
Figure 1. A. Transthoracic echocardiography detected an echo zone (78 mm × 46 mm) in the right ventricle, an echo
zone (20 mm × 15 mm) in the anterior wall of the right ventricle, and an echo zone (48 mm × 36 mm) in the pericardial
cavity outside the right ventricle; B. 64-slice computed tomographic (CT) scan demonstrated a right ventricular mass
with intra-ventricular and extra-ventricular extension and septum invasion. Slight pericardial and bilateral pleural
effusion was also found; C. Three dimensional reconstruction of 64-slice CT demonstrated a large tumor occupying
the right ventricular chamber; D. A reddish extra-ventricular tumor covering the anterior wall of the right ventricle
with old thrombi on the surface; E. The surgical specimen with the tumor section represented as fish flesh;
F. Photomicrograph demonstrating spindle-shaped cells with abundant mitotic activity.
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effective palliation after the operation, and was dis-
charged home without complications on the tenth
post-operative day. Pathological analysis proved the
diagnosis of synovial sarcoma in the right ventricle
(Fig. 1F). Immunohistochemical stainings showed
Syt++, CK5/6–, CD21/35–, S100–, Calretinin–,
CK–, CD34–, Des–, EMA–, Melan-A–, CKpan–,
SMA–, HMB45–, CD117–. Adjuvant chemothera-
py was advised, but refused by the patient. A follow-
-up telephone call six months after the surgery
showed that the patient was living with slight edema.
Discussion
Synovial sarcoma is an uncommon malignan-
cy. It occurs most frequently in the para-articular
regions of the extremities and arises from the primi-
tive arthrogenous mesenchyme with the capacity
to differentiate toward both mesenchymal and epi-
thelial cell lines. However, it is encountered in ar-
eas without any relationship to synovial structures
[9]. Primary synovial sarcoma of the heart is ex-
tremely rare, with very few reports of cases in the
literature. A thorough retrieval up to the end of
December 2009 found 35 reported cases of prima-
ry synovial sarcoma arising from the heart or peri-
cardium in 33 reports in the English language litera-
ture [4–6, 8, 10–38]. Clinical features of all such
cases are listed in Table 1.
Clinical manifestations
The male to female ratio was 27:8 with a mean
age of 34.8 years (range 13–67). The synovial sar-
coma of the heart was initially asymptomatic in early
development and presented with dyspnea and
breathlessness as the commonest complaints dur-
ing the later course. The period from morbidity to
admission was 2.3 (range 0.1–8) months on aver-
age. Corresponding clinical symptoms and physical
signs did not present until the tumor invaded sur-
rounding tissues, causing arrhythmias and tampo-
nade; or obstructed the blood flow, causing dyspnea,
heart failure; or embolized the cerebral, coronary,
and retinal vascular beds, causing embolic episodes.
Patients had no specific physical signs. Cardiac
murmurs could sometimes be heard, and dysfunc-
tions of the liver were occasionally detected.
Medical imaging features
Chest radiography and echocardiography can
be used to primarily evaluate the tumor. A chest
CT scan and magnetic resonance imaging (MRI)
Table 1. Clinical features of 35 cases of primary
synovial sarcoma of the heart.
Variable Result
Age (years) 34.8 ± 15.0
(13–67); n = 35
Sex (male/female) 27/8
Clinical manifestations:
Dyspnea 25 (71.4%)
Cough 7 (20.0%)
Syncope 5 (14.3%)
Fatigue 5 (14.3%)
Palpitation 5 (14.3%)
Chest pain 5 (14.3%)
Emaciation 4 (11.4%)
Edema 4 (11.4%)
Abdominal pain 3 (8.6%)
Vomiting 2 (5.7%)
Headache 2 (5.7%)
Fever 2 (5.7%)
Hemoptysis 2 (5.7%)
Embolism 1 (2.7%)
Admission time from 2.3 ± 2.0
onset (months) (0.1–8); n = 18
Right heart 1.8 ± 1.3 (0.1–4); n = 8
Left heart 2.6 ± 1.6 (0.75–4); n = 5
Pericardium 2.9 ± 3.2 (0.25–8); n = 5
Physical sign:
Cardiac murmur 10 (28.6%)
Jugular vein 5 (14.3%)
Ascites 3 (8.6%)
Edema 3 (8.6%)
Hepatomegaly 3 (8.6%)
Paradoxical pulse 3 (8.6%)
Laboratory examination 3 slight liver dysfunction
Location:
Right atrium 11 (29.7%)
Right ventricle 7 (18.9%)
Left atrium 5 (13.5%)
Left ventricle 2 (5.4%)
Pericardium 12 (32.4%)
Diameter [cm]: 7.6 ± 4.2 (2.0–20.0)
Right heart 7.0 ± 3.4 (2.9–15.0)
Left heart 4.1 ± 1.1 (2.0–5.1)
Pericardium 11.2 ± 4.0 (8.0–20.0)
Attachment:
Pedicled 7 (24.1%)
Sessile 22 (75.9%)
Local recurrences 7 (20.0%)
Metastasis: 11 (31.4%)
Lung 6 (54.5%)
Others 5 (45.5%)
Surgical operation:
Complete resection 11 (33.3%)
Partial resection 17 (51.5%)
Undocumented    5 (15.2%)
Adjuvant therapy 17 (48.6%)
Pathological outcome:
Biphasic type 14 (51.9%)
Monophasic type 13 (48.1%)
Diagnostic measure:
Immunohistochemistry 12 (44.4%)
Genetic test 15 (55.6%)
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could further help demonstrate the local extension
of the tumor and provide effective information for
surgery. Miller et al. [27] reported a left atrial syno-
vial sarcoma found three months after coronary ar-
tery bypass grafting. No abnormality was visualized
through the transthoracic echocardiography before
the first surgery. This showed that the tumor grew
fast, and transthoracic echocardiography could pro-
vide little information about the changes in the left
atrium. CT or MRI inspection should be regularly
carried out after surgery to enable earlier detection
of recurrences or metastases.
Special tumor location
and large tumor size
Our review found most primary synovial sar-
comas of the heart are located in the right heart.
The right to left ratio is 18:7. Tumor volume is large,
with an average diameter of 7.6 cm. According to
the statistics in the table, the average diameter of
tumors from different parts of the heart varies from
4.1 cm (left heart) to 11.2 cm (pericardium). Tumors
of the left heart are of a smaller volume. It is con-
sidered that tumors of the left heart would more
easily lead to the hemodynamics obstacle and there-
fore symptoms appear earlier. The tumors are of
different shapes: most have wide fundus and a sessile
lobular shape, while pedicled tumors only account for
24.1% (7/29) and more commonly arise from the
valve or cardiac septum.
Low surgical resection rate
and high recurrence rate
As with other malignant tumors of the heart,
surgical resection is still the mainstay of treatment
for synovial sarcoma of the heart [8]. The awkward
tumor site and large tumor volume at presentation
make complete removal of the tumor hard to
achieve in most cases. Auto transplantation after
the tumor removal and orthotopic transplantation
has been employed in a few limited cases. The com-
plete removal rate was 33.3% (11/33). However,
partial removal of the tumor could relieve the symp-
toms and prolong life. In our case, a complete re-
section of the tumor could not be achieved. Instead,
most of the tumor, along with part of the right ven-
tricular wall, was resected. The surgery turned out
to have a positive outcome. Removal of the tumor
and surrounding tissues benefits patients by alle-
viating symptoms and reducing recurrence. Pro-
tecting normal cardiac structures, including the
atrioventricular ring, may reduce post-operative
complications. The local recurrence rate after ope-
ration was 20.0% (7/35), and the metastasis rate
was 31.4% (11/35). As the commonest metastatic
part, lung metastases were detected in six of the
11 patients with definite records. Metastases to cra-
nium, extremities, pleura and liver, could also be
seen in some cases. If a diagnosis of synovial sar-
coma was considered before surgery, further in-
spections to identify distant metastases would be
necessary.
Pathological findings
Histologically, synovial sarcoma includes two
different cell types: spindle cells and epithelial cells.
It can be classified into four subtypes depending on
the relative proportion of its two cell types: (1) bi-
phasic type; (2) monophasic fibrous (spindle cell)
type; (3) monophasic epithelial type; and (4) poorly
differentiated type [39]. Immunohistochemical and
genetic tests are important in obtaining a diagno-
sis. More than 90% of patients with synovial sarco-
ma have a t(X; 18) translocation mutation, which is
not associated with other sarcomas [40]; 27 cases
with definite histological outcomes have been re-
corded, the biphasic to monophasic type ratio be-
ing 14:13.
Poor prognosis
Synovial sarcoma of the heart has a poor out-
come. As with other primary sarcomas of the heart,
most patients with synovial sarcoma of the heart die
within one year of diagnosis, more than 50% of them
from local recurrences [8]. One patient with a pri-
mary synovial sarcoma arising from the pericar-
dium had the longest survival of over 14 years proved
by long-term follow-up. Patients with complete tu-
mor removal surgery had a better prognosis. In pa-
tients with complete tumor resection, 20% (2/10)
died during follow-up, and the survivors had a mean
follow-up of 35.9 months (mean 35.9 ± 52.8, range
2–168, median 11.0); in the patients with incomplete
tumor resection, 37.5% (6/16) died during follow-
up, and the survivors had a mean follow-up of
8.8 months (mean 8.8 ± 7.1, range 1.4–22, median 5.5).
Some reports have suggested that tumors of the left
heart had a better prognosis, but this is not con-
firmed in the set of patients we have reviewed. Sta-
tistics in the table show that tumors arising from
the pericardium had a better outcome compared to
those from other parts of the heart.
Of the patients with synovial sarcomas of the
right heart, 33.3% (4/12) died during follow-up, and
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the survivors had a mean follow-up of 14.5 months
(mean 14.5 ± 17.8, range 3–60, median 8.5); of the
patients with synovial sarcomas of the left heart,
40.0% (2/5) died during follow-up, and the survivors
had a mean follow-up of 3.8 months (mean 3.8 ±
± 1.9, range 1.4–6, median 4.0); of the patients with
synovial sarcomas of the pericardium, 33.3% (3/9)
died during follow-up, and the survivors had a mean
follow-up of 35.4 months (mean 35.4 ± 58.8, range
2–168, median 13.0). Adjuvant radiotherapy may be
useful in preventing local recurrence, but the bur-
den of treatment in terms of toxicity is often unac-
ceptable because of the large size of the area re-
quiring treatment. Adjuvant chemotherapy could
obviously improve the prognosis, and ifosfamide and
amycin have shown consistent efficacy in the che-
motherapy regime for synovial sarcoma of the heart.
In the set of patients we reviewed, in the pa-
tients with adjuvant therapy, 15.4% (2/13) died dur-
ing follow-up, and the survivors had a mean follow-
up of 24.1 months (mean 24.3 ± 45.8, range 2–168,
median 12.0); in the patients without adjuvant thera-
py, 50% (7/13) died during follow-up, and the sur-
vivors had a mean follow-up of 14.4 months (mean
14.4 ± 20.6, range 1.4–60, median 5.5). In cases
with metastatic lesions, no specific chemotherapy
drugs were found.
Conclusions
Primary synovial sarcoma of the heart is ex-
tremely rare and has a poor prognosis. The clinical
symptoms are not specific. Echocardiography is the
procedure of choice to detect the tumor. But tran-
sthoracic echocardiography can provide little infor-
mation about changes in the left atrium. CT and MRI
can provide a precise view of local extensions of the
tumor before operation. Genetic tests can distin-
guish synovial sarcoma of the heart from other di-
seases. Surgical resection is still the mainstay of
treatment, with patients who receive complete tu-
mor removal having a better prognosis. Adjuvant
therapy pre- or post-operation helps prolong life. As
for all tumors with a low incidence, multicenter
studies are the only way to improve the care of pa-
tients. The key to treatment in the future is to find
new therapeutic agents. Genetic therapy has been
reported to have some efficacy [41]. Further eluci-
dation of the effects of this chromosomal abnorma-
lity may lead to better-directed therapies in future.
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